Mirasol
Pathogen Reduction Technology (PRT) System
A Proactive Approach to Improved Blood Safety
Global Blood Safety is now at the forefront of industry focus. Increased travel, climate change, evolving pathogens, emerging pandemics and the need to advance health care practices have created the necessity for a higher level of safety of blood and blood components.
This proactive approach is aimed at protecting patients from the potential dangers of donated blood. The Mirasol PRT system can help you do it by reducing the pathogen load of a broad range of disease-causing viruses, bacteria and parasites.
The system also inactivates residual white blood cells found in blood components, which may help to reduce transfusion reactions in patients.
The Mirasol PRT system allows you to meet the needs of your business by optimizing the balance of cost, efficacy and safety of your blood products.
The Mirasol PRT system is the only PRT system:
Shown to reduce incidence of a transfusion-transmitted disease in humans
That uses riboflavin (vitamin B2), a non-toxic, non-mutagenic compound, to inactivate pathogens and white blood cells
The Mirasol process has fewer steps than other PRT methods and the device can be used to treat platelets, plasma and whole blood. This simplicity helps minimize the impact to operation
The Mirasol PRT system is effective in protecting against a broad spectrum of emerging tested and untested pathogens, including bacteria, parasites, and enveloped and non-enveloped viruses;
It also inactivates white blood cells, adding an extra layer of safety for patients.
Blood products treated with the Mirasol PRT system maintain efficacy and help save patients’ lives
The Mirasol PRT system treatment can be used as an alternative to some safety procedures without introducing new risks for operators or patients.
Treatment with the Mirasol PRT system can help reduce product discard rates for blood centers and reduce the overall cost of transfusion for hospitals.
The Mirasol PRT system comes from Terumo BCT, a global leader in blood component technologies.
